more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Biotech Advances Breakthrough Cancer Treatment Results

Research Report
  ()
Sensei Biotherapeutics Inc. (SNSE:NASDAQ) is "well-positioned" to provide a clinical update on its drug targeting advanced solid tumors, Solnerstotug, in 2Q 2025, Oppenehimer & Co. Analyst Francois Brisebois writes in an updated research note.
Tags: Biotechnology / Pharmaceuticals

Pharma Innovator Reveals Groundbreaking Diabetes Treatment

Research Report
  ()
Biomea Fusion Inc.'s (BMEA:NASDAQ) drug could capture a significant share of the diabetes market, given the large target population globally, D. Boral Capital Analyst Jason Kolbert writes in an updated research note. Read why his target price is nearly a nearly 3,000% increase per share.
Tags: Biotechnology / Pharmaceuticals

AI-Driven Discovery Unveils Cancer Therapy Breakthrough, Exceeding Projections

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments. Discover how these innovations could reshape oncology research.
Tags: Biotechnology / Pharmaceuticals

Revenue Surge and Breakthrough Margins Fuel Growth in Critical Care Tech

  ()
CytoSorbents Corp. (CTSO:NASDAQ) reported a 22%-25% revenue jump in Q4, driven by strong performance and expanding global adoption of its flagship product. Read how regulatory breakthroughs in 2025 could redefine the company's market presence.
Tags: Biotechnology / Pharmaceuticals

Drug Innovator Launches Pivotal Cancer Trial Breakthrough

Research Report
  ()
Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) has the potential to generate hundreds of millions of dollars over the next decade with its drug candidates, an H.C. Wainwright & Co. analyst wrote in a January 2 research note.
Tags: Biotechnology / Pharmaceuticals

Pharma Innovator Unlocks Multi-Disease Treatment Potential

Research Report
  ()
Quince Therapeutics Inc. is "positioned for a transformative year" in 2025 with a solid cash position of US$47.8 million as of the third quarter of 2024. Find out why one analyst gives the stock a Buy rating.
Tags: Biotechnology / Pharmaceuticals

Miami Biopharma Sells Part of Business and Begins New Clinical Trial

Research Report
  ()
Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating.
Tags: Biotechnology / Pharmaceuticals

Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug

Research Report
  ()
NewAmsterdam Pharma Company N.V.'s (NAMS:NASDAQ) drug obicetrapib is a "once-in-a-generation" drug for cardiovascular disease, an analyst wrote in a research note while initiating coverage on the company. See what rating the stock got and its price per share target.
Tags: Biotechnology / Pharmaceuticals

Analyst Sees Major Growth for Biopharma With Weight-Loss Drug

Research Report
  ()
Recent successes of weight-loss drugs like Ozempic and Wegovy have led H.C. Wainwright & Co. Analyst Ed Arce to be "intrigued" by MetaVia Inc.'s (MTVA:NASDAQ) new drug candidate.
Tags: Biotechnology / Pharmaceuticals

Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy

  ()
Gain Therapeutics Inc. (GANX:NASDAQ) has announced the initiation of its Phase 1b clinical trial for GT-02287, a lead candidate targeting Parkinsons disease (PD), following regulatory approval in Australia. Read more about the trial aiming to redefine Parkinsons treatment and its potential global impact.
Tags: Biotechnology / Pharmaceuticals

Maryland Biotech Gains Regulatory Approval

Research Report
  ()
Gain Therapeutics Inc. (GANX:NASDAQ) recently received Australian regulatory approval to begin GT-02287 evaluation in Parkinson's disease (PD) patients.
Tags: Biotechnology / Pharmaceuticals

Pharma Co. Signs License Agreement With Boston Medical Center

Research Report
  ()
60 Degrees Pharmaceuticals Inc. (SXTP:NASDAQ) announced a partnership to advance Arakoda (tafenoquine) for babesiosis with Boston-based Tufts Medical Center, according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

FDA Expedites Review of Gene Therapy Co.'s Drug

  ()
Clinical stage genetic medicines company MeiraGTx Holdings Plc (MGTX:NASDAQ) says the FDA has granted regenerative medicine advance therapy (RMAT) designation to one of its treatments that could help thousands of patients. Read why one analyst thinks the stock is undersold.
Tags: Biotechnology / Pharmaceuticals

Biopharma Using AI to Find Promising Cancer Drug Candidates

  ()
Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) summarizes its achievements for 2024 and outlines its goals for the coming year. Find out how the company is using AI to accelerate drug development.
Tags: Biotechnology / Pharmaceuticals

New Data Supports BLA Package

Research Report
  ()
Annexon Inc. (ANNX:NASDAQ) recently released real-world evidence data comparing it's ANX005 to standard treatments for Guillain-Barr Syndrome (GBS), according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says

  ()
Clinical-stage biotechnology company Gain Therapeutics Inc.'s (GANX:NASDAQ) drug treating Parkinson's disease could be a "US$4 billion drug," according to one analyst who recently initiated coverage on the Maryland company.
Tags: Biotechnology / Pharmaceuticals

California Biopharma Shows Promising Phase 1 Data

Research Report
  ()
Artelo Biosciences Inc. (ARTL:NASDAQ) recently reported promising Phase 1 results from its CAReS trial evaluating ART27.13 for cancer-related anorexia, according to a D. Boral Capital research note.
Tags: Biotechnology / Pharmaceuticals

FDA Decision on Drug for Bone Marrow Due Early 2025

Research Report
  ()
The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

Drug Trial Shows Positive Interim Results for ALS Treatment

  ()
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announced the release of a positive interim analysis of its treatment of Amyotrophic Lateral Sclerosis (ALS). Find out why one analyst says the drug has "potential" to treat the disease and maybe others.
Tags: Biotechnology / Pharmaceuticals

Approval Sought in Japan for New Drug to Lower Cholesterol

Research Report
  ()
The U.S. biopharma behind the drug is "pushing for accelerated adoption and expansion into additional territories," noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative

  ()
Leading regenerative medicine company Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces agreement to explore fighting type I diabetes in Saudi Arabia. Read why one analyst believes the company's technology is "advanced."
Tags: Regenerative MedicineBiotechnology / Pharmaceuticals

Is This California Biopharma Co. In the Right Place at the Right Time?

Research Report
  ()
Roth MKM analyst Dr. Jonathan Aschoff highlighted GT Biopharma Inc.'s (GTBP:NASDAQ) development of unique precision therapeutic agents using camelid-derived nanobodies.
Tags: Biotechnology / Pharmaceuticals

Biotech Initiates Phase III Trial for Heart Disease Drug

  ()
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock.
Tags: Biotechnology / Pharmaceuticals

Analyst Says Biotech's Data Supports Advancement Into Phase III

Research Report
  ()
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note.
Tags: Biotechnology / Pharmaceuticals

Rising Revenue and Strategic Pipeline Advances Propel Biotech Growth Trajectory

  ()
Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. Read the details on this announcement and some of the primary drivers behind the rise.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 56 Next